^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    IDO1 expression

    i
    Other names: IDO1, IDO, INDO, Indoleamine 2,3-dioxygenase 1
    Entrez ID:
    3620
    Related biomarkers:
    Expression
    Apply
    Epacadostat Before Surgery in Treating Patients With Newly Diagnosed Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT02042430)
    Phase 1
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    03/11/2024
    Initiation :
    08/25/2014
    Primary completion :
    03/31/2016
    Completion :
    03/07/2025
    IDO1
    |
    IDO1 expression
    |
    epacadostat (INCB024360)
    Pembrolizumab TX-naive Distant Mets Melanoma and Use of (C11-AMT) PET at Baseline as Imaging Biomarker (NCT03089606)
    Phase 2
    UNC Lineberger Comprehensive Cancer Center
    Completed
    Last update posted :
    11/15/2023
    Initiation :
    04/19/2017
    Primary completion :
    04/01/2021
    Completion :
    07/01/2023
    LAG3 • HAVCR2 • CD27
    |
    IDO1 expression
    |
    Keytruda (pembrolizumab)
    Study of Epacadostat (INCB024360) Alone and In Combination With Pembrolizumab (MK-3475) With Chemotherapy and Pembrolizumab Without Chemotherapy in Participants With Advanced Solid Tumors (MK-3475-434) (KEYNOTE-434) (NCT02862457)
    Phase 1
    Merck Sharp & Dohme LLC
    Completed
    Last update posted :
    08/19/2022
    Initiation :
    08/23/2016
    Primary completion :
    11/20/2020
    Completion :
    11/20/2020
    EGFR • PD-L1 • ALK • IDO1
    |
    IDO1 expression
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • albumin-bound paclitaxel • pemetrexed • epacadostat (INCB024360)
    Neoadjuvant Celecoxib in Newly Diagnosed Patients With Endometrial Carcinoma (CELEBRIDO) (NCT03896113)
    Phase 2
    Cliniques universitaires Saint-Luc- Université ...
    Unknown status
    Last update posted :
    01/10/2020
    Initiation :
    11/13/2019
    Primary completion :
    06/30/2022
    Completion :
    06/30/2022
    CD8 • IDO1 • CD4
    |
    IDO1 expression
    |
    celecoxib oral
    An Open Label Phase II Study Combining Nivolumab and Celecoxib in Patients With Advanced " Cold " Solid Tumors (NICE-COMBO) (NCT03864575)
    Phase 2
    Cliniques universitaires Saint-Luc- Université ...
    Unknown status
    Last update posted :
    07/12/2019
    Initiation :
    08/15/2019
    Primary completion :
    06/15/2021
    Completion :
    06/15/2021
    BRAF • IDO1
    |
    BRAF mutation • IDO1 expression • IDO1 positive
    |
    Opdivo (nivolumab) • celecoxib oral
    Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma (NCT01961115)
    Phase 2
    Fred Hutchinson Cancer Center
    Completed
    Last update posted :
    06/08/2018
    Initiation :
    09/13/2013
    Primary completion :
    10/31/2016
    Completion :
    05/18/2017
    BRAF • CD8 • IFNG • CTLA4 • IDO1 • CD4
    |
    BRAF V600E • BRAF V600 • CD8 expression • IDO1 expression
    |
    epacadostat (INCB024360)
    Neoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab Alone (NCT02736123)
    Phase 1/2
    University of Pittsburgh
    Withdrawn
    Last update posted :
    09/20/2017
    Initiation :
    10/01/2016
    Primary completion :
    02/09/2017
    Completion :
    02/09/2017
    PD-L1 • CD8 • IDO1
    |
    PD-L1 expression • IDO1 expression
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)
    Trial of SBRT With Concurrent Ipilimumab in Metastatic Melanoma (NCT02406183)
    Phase 1
    Radiotherapie
    Completed
    Last update posted :
    01/10/2017
    Initiation :
    03/01/2015
    Primary completion :
    08/01/2016
    Completion :
    08/01/2016
    IDO1 • FOXP3
    |
    IDO1 expression
    |
    Yervoy (ipilimumab)